An observational study in Inflammatory Bowel Disease, sponsored by Sandoz. Active, not recruiting at 51 sites in 2 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Sandoz (formerly part of Novartis) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 143 studies in Inflammatory Bowel Diseases with a site in France — 31 open to participants now, 42 under way, 7 of them phase 3. Inflammatory Bowel Diseases · France.
Among the 143 studies in Inflammatory Bowel Diseases with a site in France, this one is the 16th largest by planned enrollment of the 59 observational ones that give a count, is one of 7 that started in 2023, is one of 59 observational ones, reaches primary completion later than 8 of the 41 other live ones, and was the 110th registered.
1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.
Browse Inflammatory Bowel Diseases studies →31 of the 143 studies in Inflammatory Bowel Diseases with a site in France are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in France
Ages 18+
Palisade Bio · Sites in France, United States, Canada and 9 more countries
Ages 18–75
Raincy Montfermeil Hospital Group · Sites in France
Ages 18+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
Spyre Therapeutics, Inc. · Sites in France, United States, Argentina and 33 more countries
Ages 18–75
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
143 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 27 · Phase 4 2
First in 1990; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 562 is above the median of 140 across 626 observational studies indexed under Inflammatory Bowel Diseases.
Median enrollment 124 across the 84 interventional studies, 220 across the 59 observational. Of the 95 that completed or were terminated, 25 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 143 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sandoz, one of the names counted as Novartis. Under that name alone:
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Novartis has 5 studies filed under Inflammatory Bowel Diseases — fewer than ten, so there is no comparison to draw.
10 of the studies in Inflammatory Bowel Diseases with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04997733Phase 3Assistance Publique - Hôpitaux de ParisFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal | 2027-05-22 |
| NCT05923073Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease | 2027-10-27 |
| NCT06261320Polyclinique de l'EuropeMesotherapy Treatment of Irritable Bowel Syndrome | 2026-12-31 |
| NCT06805890Assistance Publique Hopitaux De MarseilleStudy of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology | 2027-03-24 |
| NCT05251415University Hospital, ToulouseClinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases | 2027-04-04 |
Add all 10 to your calendar (.ics) → With an account.
Among the 143 studies in Inflammatory Bowel Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An international, multicenter, non-interventional, prospective, post-authorization, descriptive, non-PASS, study.
The main purpose of this non-interventional study is to assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation in Inflammatory Bowel Disease (IBD) patients.
Primary data will be collected at each data collection time point (visits will be according to local clinical practice). Data will be collected based on the information reported in the medical records. This study does not impose a therapy protocol, procedure or change in routine medical practice. Apart from self-administered questionnaires, no additional examinations or assessments are required, consequently there are no additional medical risks for the patients. The total duration of the study will be 36 months (3 years). The recruitment period will be for 2 years with individual patient follow-up for up to 1 year.
It is expected that patients will visit their physicians at regular intervals depending on local specific clinical practices. Four time points for data collection will be defined:
Patients for whom the investigator has decided to initiate treatment with Hyrimoz® in accordance with the approved SmPC and local clinical practice, will be eligible to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must meet all of the following criteria at Baseline:
Patients meeting one of the following criteria:
Exclusion Criteria:
Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients prescribed with Hyrimoz
Other: Hyrimoz
There is no treatment allocation. Patients administered Hyrimoz by prescription that have started as routine medical treatment will be enrolled.
Also known as: adalimumab biosimilar
Percentage of patients who remain on Hyrimoz® at 6 months after treatment initiation
Assess patient retention with Hyrimoz® treatment up to 6 months after treatment initiation
Time frame: Up to 6 months
Percentage of patients who discontinue Hyrimoz
Percentage of patients who discontinue Hyrimoz® at T2 and T3 due to: * Lack of efficacy. * Intolerance/Adverse event(s) or special scenario. * Patient's decision * Nocebo effect * Other reasons.
Time frame: 6 months, 12 months
Percentage of patients with high level of treatment satisfaction using TSQM-9 questionnaire
To assess patients' treatment satisfaction (based on 9-item Treatment Satisfaction Questionnaire for Medication \[TSQM 9\], the percentage of patients with high level of treatment satisfaction (score ≥ 39) will be collected. The TSQM-9 is declined with 9 questions about patient treatment satisfaction. Each answer gives a number of points depending of the question and the answer. The final score is the sum of points in each question. This questionnaire score from 9 to 59 points. In HYRISS study, we estimate that patient with \< 39 pts in TSQM-9 are considered with a low satisfaction for the medication (satisfaction under 60%).
Time frame: 3 months, 6 months, 12 months
Percentage of patients with high level of treatment adherence using adapted CQR5 questionnaire
To assess adherence/compliance to treatment (based on 5 item Compliance Questionnaire for Rheumatology \[CQR5\] adapted for gastroenterologist), percentage of patients with high level of treatment adherence (score ≥ 15) using adapted CQR5 questionnaire will be collected. The CQR5 is declined with 5 questions about patient compliance to the treatment. Each answer gives from 1 to 4 points depending of the answer. The final score is the sum of points in each question. This questionnaire score from 5 (very low compliance) to 20 points (very strong compliance).
Time frame: Baseline, 3 months, 6 months, 12 months
Percentage of patients with the perception of a high level of disease activity using VAS scale
To assess the patient's reported disease activity, percentage of patients with the perception of a high level (score ≥ 6) of disease activity will be collected using visual analog scale \[VAS\]. This visual analogue scale (VAS) is an instrument designed to document the disease activity. Patients are asked to rate their disease activity on a visual analogue scale (VAS): How active has your disease been this week? From 0 (Not active at all) to 10 cm (Extremely active).
Time frame: Baseline, 3 months, 6 months, 12 months
Percentage of patients with a good perception about biosimilars using VAS scale
To assess the patient's reported perception about biosimilars at the inclusion visit, percentage of patients with a good perception (score ≥ 6) about biosimilars using VAS scale will be measured. This visual analogue scale (VAS) is an instrument designed to document the perception of the patient about biosimilar. Patients are asked to rate their perception of biosimilar medicine on a visual analogue scale (VAS): Are you confident in using biosimilar? From 0 (I have no confidence at all) to 10 cm (I have a great confidence).
Time frame: Baseline
Percentage of patients in remission
Remission defined as Harvey-Bradshaw Index \[HBI\] ≤ 4 \[for Crohn's Disease\] or partial Mayo score ≤ 1 \[for Ulcerative Colitis\]
Time frame: Baseline, 3 months, 6 months, 12 months
Crohn's disease activity measurement: Harvey Bradshaw Index [HBI]
Crohn's disease activity will be measured with HBI score. Score is interpreted: \<4: Remission 4-7: Mild disease 8-16: Moderate disease \>16: Severe disease
Time frame: Up to 12 months
Ulcerative colitis activity measurement: partial Mayo calculation score
Ulcerative colitis activity will be measured using partial Mayo calculation score. Score is interpreted: ≤ 1: Remission 2 - 4: Low activity disease 5 -6: Moderate disease 7 - 9: Severe disease
Time frame: Up to 12 months
Pattern of Hyrimoz® utilization
Pattern of Hyrimoz® utilization to be collected
Time frame: Up to 12 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Dec 2025, 33 months.
Of 37 industry-sponsored observational studies under Inflammatory Bowel Diseases, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 44. This study's 33 months is close to that.
Counting every sponsor, half of 281 studies reached it within 36 months; a quarter within 20 and three quarters within 122.
Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Mar 2027, on Nov 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.